SelectQuote (SLQT) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
18 Sep, 2026Executive summary
Annual Meeting scheduled for November 10, 2026, will be held virtually, with voting on key proposals including director elections, auditor ratification, executive compensation, a reverse stock split, and potential adjournment.
Only stockholders of record as of September 18, 2026, are eligible to vote; multiple voting methods are available, including online, phone, and mail.
Board recommends voting in favor of all proposals, including the reverse stock split to address NYSE listing requirements.
Voting matters and shareholder proposals
Election of three Class I directors to serve until 2029.
Ratification of Deloitte & Touche LLP as independent auditor for fiscal year ending June 30, 2027.
Advisory vote on executive compensation (say-on-pay).
Proposal to effect a reverse stock split (1-for-10 to 1-for-20) and reduce authorized shares accordingly.
Adjournment proposal to solicit additional proxies if needed for the reverse stock split.
Board of directors and corporate governance
Board consists of eight directors, with a majority classified as independent under NYSE standards.
Board is divided into three classes with staggered three-year terms; separation of CEO and Chairman roles.
Four standing committees: Audit, Compensation and Talent Development, Nominating and Corporate Governance, and Healthcare Oversight.
Regular executive sessions held without management; robust stockholder engagement program in place.
Latest events from SelectQuote
- Revenue and cash flow grew in 2026; 2027 targets higher margins and efficiency gains.SLQT
Q4 2026 - Diversified insurance and healthcare platform achieves strong growth and operational efficiency.SLQT
Investor presentation - Q3 FY2026 revenue up 6% to $430.9M, net income $40.2M, with robust segment growth and outlook.SLQT
Q3 2026 - Revenue up 12% to $537.1M, net income $69.3M, and guidance cut by $40M amid external headwinds.SLQT
Q2 2026 - Board recommends approval of all 2025 meeting proposals, emphasizing performance and governance.SLQT
Proxy Filing - All proposals passed, including director elections and auditor ratification, with no shareholder questions.SLQT
AGM 2025 - FY2024 results surpassed expectations, with robust growth in revenue and profitability.SLQT
Q4 2024 - Revenue up 26% with strong pharmacy growth; $100M securitization boosts capital flexibility.SLQT
Q1 2025 - Q2 revenue up 19% to $481.1M, net income $53.2M, $350M equity investment secured.SLQT
Q2 2025